With the removal of Relyvrio (sodium phenylbutyrate/taurursodiol) from the market, Amylyx Pharmaceuticals, Inc. will lose its sole commercial revenue stream and return its focus to pipeline development. The company announced on 4 April that it will withdraw Relyvrio from the US and Canada, where it is sold as Albrioza, immediately due to lack of efficacy for amyotrophic lateral sclerosis (ALS).
Key Takeaways
- The withdrawal of Relyvrio from the market for ALS was expected but is a disappointment for the company, investors and patients.
The update was expected after the Cambridge, MA-based company announced in March that the confirmatory Phase III PHOENIX trial testing...
